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Abstract  
Pulmonary Arterial Hypertension (PAH) is a devastating cardiovascular disorder 
characterised by the remodelling of pre-capillary pulmonary arteries. The vascular 
remodelling observed in PAH patients results from excessive proliferation and apoptosis 
resistance of pulmonary arterial smooth muscle (PASMCs) and endothelial cells (PAECs). 
We have previously demonstrated that mutations in the type II receptor for bone 
morphogenetic protein (BMPRII) underlie the majority of the familial and inherited forms of 
the disease. We have further demonstrated that BMPRII deficiency promotes excessive 
proliferation and attenuates apoptosis in PASMCs, but the underlying mechanisms remain 
unclear. The major objective of this study is to investigate how BMPRII deficiency impairs 
apoptosis in PAH. Using multidisciplinary approaches, we demonstrate that deficiency in the 
expression of BMPRII impairs apoptosis by modulating the alternative splicing of the 
apoptotic regulator, Bcl-x (B-cell lymphoma X) transcripts: a finding observed in circulating 
leukocytes and lungs of PAH subjects, hypoxia-induced PAH rat lungs as well as in 
PASMCs and PAECs. BMPRII deficiency elicits cell specific effects: promoting the 
expression of Bcl-xL transcripts in PASMCs whilst inhibiting it in ECs, thus exerting 
differential apoptotic effects in these cells. The pro-survival effect of BMPRII receptor is 
mediated through the activin receptor like kinase 1 (ALK1) but not the ALK3 receptor. 
Finally, we show that BMPRII interacts with the ALK1 receptor and pathogenic mutations in 
the BMPR2 gene abolish this interaction. Taken together, dysfunctional BMPRII 
responsiveness impairs apoptosis via the BMPRII-ALK1-Bcl-xL pathway in PAH. We 
suggest Bcl-xL as a potential biomarker and druggable target. 
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INTRODUCTION 
Pulmonary Arterial Hypertension (PAH) is a devastating and incurable cardiovascular 
disorder characterised by the remodelling of pre-capillary pulmonary arteries. The condition 
is characterised by abnormal proliferation and apoptosis resistance of pulmonary arterial 
smooth muscle cells (PASMCs), endothelial cells (PAECs) and fibroblasts, leading to 
elevated pulmonary artery pressure, right-heart failure, and premature death (1,2). 
Heterozygous loss of function mutations in the bone morphogenic protein type II receptor 
(BMPR2) gene (3) underlie the majority (>80%) of familial and heritable PAH and can be 
identified in a substantial proportion (40%) of isolated PAH cases (3,4). We have 
determined that disease-associated nonsense mutations trigger degradation of the BMPR2 
transcript via the nonsense-mediated decay (NMD) process. This contributes to a 
stoichiometric imbalance in the receptor complex and dysfunctional signalling (5). 
Furthermore, we have found a number of heterozygous mutations in SMAD1, SMAD4 and 
SMAD9 genes in European and Japanese cohorts, which were excluded for BMPR2 
mutation. Each mutation impacts upon transcript integrity, reduces bone morphogenic 
protein (BMP) signalling, and diminishes expression of the Id1-3 genes (6). Recent 
investigations have identified novel mutations in BMP9, EIF2KA4, ATP13A3, AQP1 and 
SOX17 genes, but they represent an infrequent cause of the disease (7,8). Furthermore, 
reduced BMPRII expression has been observed in non-genetic forms of PAH in humans (9) 
and animal models (10). These results imply that the impaired BMPRII pathway may cause 
susceptibility to abnormal vascular homeostasis leading to PAH.  
A balance between pro- and anti-apoptotic factors determines cell fate. The B-cell lymphoma 
2 (Bcl2) family proteins are well known for their roles in regulation of apoptosis. Bcl-2, Bcl-xL, 
Bcl-w proteins constitute the anti-apoptotic members of this family whilst Bax, Bid, Bad and 
Bcl-xS proteins belong to the pro-apoptotic group. The expression of anti-apoptotic 
regulators such as the Bcl2 gene is increased in both sporadic and familial PAH lung tissues 
(11). A member of this family of genes is B-cell lymphoma X (Bcl-x), which generates both 
pro- (Bcl-xS) and anti-apoptotic (Bcl-xL) isoforms via alternative splicing (12). In normal 
PASMCs, BMP signalling downregulates the expression of Bcl2 (13). We and others have 
shown that SMAD-independent pathways such as p38MAPK and NF-κB are activated in 
experimental models of PAH, and that these pathways have been shown to enhance the 
expression of Bcl-xL isoform (14), thereby exerting an anti-apoptotic phenotype. We have 
previously demonstrated that apoptosis is greatly reduced in mouse PASMCs harbouring the 
pathogenic BMPR2 (p.R899X) mutation and the BMPRII deficiency potentiates the 
transforming growth factor β (TGFβ) signalling pathway. TGFβ induces apoptosis in human 
B cells by transcriptional activation of Bcl-xL (15). Taken together, these observations 
indicate a relationship between BMP/TGFβ signalling pathways and the regulation of Bcl2 
family of proteins. However, how dysfunctional BMPRII signalling regulates the alternative 
splicing of Bcl-x transcripts in PAH remains to be investigated. 
We and others have demonstrated that in PASMCs isolated from PAH subjects (PAH-
PASMCs), the anti-proliferative and pro-apoptotic effects of BMPs (2, 4, 7 and 9), are greatly 
reduced (6,16-18). In vascular endothelial cells,  BMP ligands elicit a pro-proliferative 
response (19). In addition, BMPs protect vascular and blood-derived endothelial cells from 
apoptosis (4) and this protection seems to be mediated by the BMPRII receptor, as 
inactivating mutations in the receptor trigger endothelial cell apoptosis (20). We have 
previously demonstrated that BMPRII deficiency elicits pro-proliferative and anti-apoptotic 
phenotype in PASMCs via the TGFβ-associated kinase 1 (TAK1), but the underlying 
mechanisms by which apoptosis resistance is controlled in PAH remains unclear.  
In this report, we have investigated the underlying mechanisms leading to apoptosis 
resistance in PAH. We have shown that the expression of anti-apoptotic Bcl-xL transcripts is 
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greatly increased in the lungs and circulating leukocytes of PAH patients with and without 
BMPR2 mutations. The expression of Bcl-xL transcripts is also increased in hypoxic PAH rat 
lungs and in PAH-PASMCs harbouring the BMPR2 (p.R899X) mutation. Selective inhibition 
of Bcl-xL protein by a small molecule agent induces apoptosis in PAH-PASMCs. In 
endothelial cells, siRNA knock down of either the BMPR2 or the ALK1 gene promotes 
endothelial cell apoptosis. Overexpression of the BMPRII receptor activates the expression 
of Bcl-xL and inhibits caspase 3/7 activities. The pro-survival effect of BMPRII receptor is 
mediated through the ALK1 but not the ALK3 receptor. Finally, we have shown that BMPRII 
interacts with the ALK1 receptor and mutations in the BMPR2 gene, abolish this interaction 
and reduce BMP-responsive reporter activation. Taken together, these observations suggest 
that the BMPRII-ALK1-Bcl-xL pathway regulates cell-specific apoptosis in PAH. Whilst 
determination of the ratio of Bcl-xL and Bcl-xS transcripts offers the opportunity for a novel 
biomarker, targeting the BMPRII-Bcl-xL axis may provide a novel therapeutic intervention in 
PAH.  
 
RESULTS 
The expression of anti-apoptotic Bcl-xL transcripts is increased in circulating 
leukocytes and lungs of PAH patients  
Alternative splicing of the Bcl-x gene, a key regulator of apoptosis, generates the pro-
apoptotic (Bcl-xS) and anti-apoptotic (Bcl-xL) isoforms (Figure 1A) (12). To determine 
whether alternative splicing of Bcl-x transcripts is altered in PAH patients, semi-quantitative 
PCR analyses were performed on circulating leukocytes of six PAH patients and seven 
control subjects. Out of the six PAH patients studied, five patients harboured mutations in 
the BMPR2 gene. The BMPR2 mutations were nonsense (p.L287X), frameshift (c.A796fsX6) 
and deletion (c.A497-503del, c.768+3delA), all of which are likely to introduce a premature 
termination codon into the reading frame. A substantial reduction in the pro-apoptotic 
transcript, Bcl-xS, and an increase in the anti-apoptotic Bcl-xL isoform were observed in 
PAH cases compared to control subjects (Figure 1B-C). We next determined the 
relationship between defective BMPRII signalling and Bcl-x splicing in lung tissues of a PAH 
patient who had undergone combined heart and lung transplantation. The PAH patient 
studied harboured a nonsense (p.T835X) BMPR2 mutation. Consistent with the leukocyte 
data, we observed significantly increased expression of the anti-apoptotic isoform Bcl-xL 
over Bcl-xS in PAH lungs compared with the control (Figure 1D-E). These results indicated 
that there might be a correlation between preferential expression of the anti-apoptotic Bcl-xL 
over the pro-apoptotic Bcl-xS transcripts in PAH patients with and without BMPR2 mutations.  
BMPRII deficiency promotes the anti-apoptotic Bcl-xL expression in hypoxia-induced 
PAH rat lungs 
As we observed an increased Bcl-xL expression in PAH cases who do not harbour a BMPR2 
mutation, we were keen to determine whether the expression of Bcl-xL was upregulated in a 
non-genetic PAH experimental model. Therefore, the hypoxia-induced rat model of PAH (17) 
was used to investigate the relationship between reduced levels of the BMPRII receptor and 
the alternative splicing of Bcl-x. Two weeks of chronic hypoxia reduced the level of BMPR2 
expression (Figure 2A) and increased the ratio of Bcl-xL to Bcl-xS and Bcl-xL to GAPDH in 
rat lung tissues (Figure 2B-D), confirming a link between BMPRII deficiency and preferential 
expression of the anti-apoptotic Bcl-xL transcripts.  
The expression of anti-apoptotic Bcl-xL transcripts is increased in both primary PAH-
PASMCs and hTERT-PASMCs harbouring a pathogenic BMPR2 mutation 
Having observed an increased level of Bcl-xL expression in PAH patient samples and in 
PAH rat lungs, we were keen to investigate alternative splicing of the Bcl-x gene in cells 
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including PASMCs and ECs, which are involved in the remodelling of small pulmonary 
arteries.  We first investigated the expression of Bcl-x transcripts in human PASMCs. These 
cells were isolated from explanted lung samples from a PAH patient harbouring a pathogenic 
mutation (p.R899X) in the BMPR2 gene. PAH-PASMCs and commercially available wild-
type PASMCs were grown in tissue culture plates until confluency and their total RNAs were 
isolated. Semi-quantitative PCR was carried out to determine the expression of Bcl-x 
transcripts.  Low level expression of Bcl-x transcripts was observed in wild-type PASMCs 
whilst the expression of Bcl-xL transcripts was significantly increased in PAH-PASMCs 
(Figure 3A-B). We further investigated the expression of Bcl-xL transcripts in PAH-PASMCs 
immortalized by the expression of human telomerase gene (hTERT) (Nasim et al., 
unpublished data). The expression of Bcl-xL transcripts was also increased in these cells 
(Figure 3A-B). 
Dysregulated BMPRII-mediated signalling impairs caspase activity in PASMCs 
BMPRII mediated signalling elicits pro-apoptotic effect in PASMCs (17) . To determine the 
relationship between pro-apoptotic effects of BMPRII and the preferential expression of Bcl-
xL transcripts (Figure 3C), we took advantage of PASMCs derived from knock-in (K-I) mice 
harbouring the PAH-associated BMPR2 nonsense mutation (p.R899X). These mice were 
asymptomatic at the age of three months but developed age-related PAH at the age of six 
months (4) . PASMCs were isolated from asymptomatic wild-type (bmpr2 +/+) and mutant 
(bmpr2 R899X+/-) mice and the rate of apoptosis was determined by measuring cysteinyl 
aspartate proteases (caspase) activity using commercially available kits (Promega) following 
manufacturer’s instructions. Consistent with our previous observations, the basal activity 
level of caspases 3 and 7 was attenuated in mutant cells compared with wild-type (Supp 
Figure 1) (17) . We earlier demonstrated that staurosporine (ST), a known inducer of 
apoptosis showed differential effects, with ST- induced caspase activity seemingly greater in 
mutant cells than wild-type (17). We further characterized the pro-apoptotic effect of BMP 
signalling on ST-induced apoptosis by stimulating the cells with BMP9 ligand (Figure 3D). In 
wild-type cells, the caspase activity was further increased following ligand stimulation, which 
is consistent with the previous finding of BMP-dependent caspase activation (21). The pro-
apoptotic effect of BMP stimulation was absent in BMPRII deficient cells. In these cells, 
BMP9 inhibited staurosporine induced cell death in a dose dependent manner (Figure 3D).  
Selective inhibition of Bcl-xL by a chemical agent induces apoptosis in PAH-PASMCs 
We hypothesized that BMPRII dysfunction potentiates the apoptotic-resistant phenotype 
through the upregulation of Bcl-xL, and that selective inhibition of Bcl-xL induces apoptosis 
(Figure 3E). We used PAH-PASMCs harbouring the BMPR2 (p.R899X) mutation as these 
cells showed reduced level of apoptosis compared with wild-type (17). PASMCs were treated 
with 2, 3 DCPE hydrochloride for 48 hours and the caspase activity was determined. The 
compound significantly increased apoptosis in PAH-PASMCs in a concentration dependent 
manner (Figure 3F). As expected, it also induced apoptosis in wild-type PASMCs.  
BMPRII-mediated signalling promotes the expression of Bcl-xL transcripts in PAECs 
and HEK293T cells 
Having characterised the expression of Bcl-xL transcripts in PASMCs, we then determined 
Bcl-x splicing in PAECs following knock-down of either BMPRII or ALK1 receptors. siRNAs 
targeting either the BMPR2 or ALK1 gene significantly inhibited the expression of Bcl-xL 
transcripts (Figure 4A-B). qPCR analyses of BMPR2 and ALK1 transcripts showed reduced 
level of these transcripts in cells transfected with siRNAs compared with that of controls 
(Supp Figure 2A-B). Of note, little or no expression of Bcl-xS transcripts was observed in 
PAECs. Next, we determined the effect of BMPRII overexpression on Bcl-x expression. For 
this experiment, we selected the human embryonic kidney (HEK293T) cells as the 
transfection efficiency is higher in these cells compared with PASMCs and PAECs. Cells 
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were co-transfected with a plasmid harbouring the wild-type BMPRII receptor. We found that 
the expression of Bcl-xL transcripts was increased in cells overexpressed with the BMPRII 
receptor compared with the untreated control (Figure 4C-D). Whilst we found that HEK293T 
cells treated with BMP9 ligand (10ng/ml) increased the level of Bcl-xL transcripts, the ligand 
elicited no discernible effect on the preferential expression of Bcl-x in PAECs (Supp Figure 
3A-B).   
Knock down of either BMPRII or ALK1 promotes endothelial cell apoptosis 
As BMPRII mediated signalling has been shown to protect human PAECs from apoptosis 
(20), we used siRNAs against either BMPRII or ALK1 and determined their effect on 
endothelial cell apoptosis by measuring caspase 3/7 activities. Knock down of either BMPRII 
or ALK1 increased caspase 3/7 activities, indicating pro-survival roles of BMP signalling in 
PAECs (Figure 4E).    
BMPR2 mutations found in PAH patients reduce pro-survival effects  
We were interested to investigate the effect of a wide range of mutations identified in PAH 
patients on pro-survival activity. To investigate this, we employed HEK293T cells as in these 
cells BMPRII-mediated signalling increased the expression of pro-survival Bcl-xL isoform. 
The pro-survival effect of BMPRII-mediated signalling was investigated by transfecting 
HEK293T cells with plasmids harbouring either BMPRII wild-type or a wide range of mutant 
receptors (Figure 4F). Cell viability was measured using Cell-Titre Glo Cell Viability Assay 
Kit (Promega) following manufacturer’s instructions. Cell viability was increased in cells 
transfected with the wild-type receptor suggesting a pro-survival role of BMPRII-mediated 
signalling in HEK293T cells (Figure 4G). In contrast, the cell viability was significantly 
reduced in cells transfected with the mutant p.C118W, p.D485G, p.N51K, p.S532X, pR899X 
and p.R899P plasmids, indicating that the pro-survival effects of BMPRII receptor are greatly 
reduced in the presence of pathogenic mutations (Figure 4G). However, cells transfected 
with the p.E503D mutant showed no discernible effects. Of note, we previously 
demonstrated that this mutation was capable of mediating BMP signalling at the level 
comparable to the wild-type receptor (5). Collectively, these data suggest that BMPR2 
dysfunction elicits cell-specific effects. The receptor dysfunction induces anti-apoptotic 
effects in PASMCs whilst it exerts anti-survival effects in PAECs and HEK293 cells. 
BMP signalling inhibits caspase 3/7 activities via the ALK1 receptor  
Having identified pro-survival effects of BMPRII-mediated signalling in both endothelial and 
HEK293T cells, we were keen to investigate the underlying mechanisms by which BMPRII 
regulates anti-apoptotic effects (Figure 5A). First, we investigated the effect of BMP 
signalling on apoptosis. Briefly, HEK293T cells were stimulated with BMP4 ligand (10ng/ml) 
overnight in the presence of ST and the activities of caspase 3/7 activities were determined. 
We found that BMP4 stimulation reduced ST-induced caspase activities (Figure 5B). Next, 
the BMP signalling promoting activity of BMP4 ligand and BMPRII receptor was tested using 
the BMP-responsive 3GC2-Lux reporter assay (22) as previously described by us (5). 
HEK293T cells were stimulated with the ligand (10ng/ml) at various time points (30 mins, 1h, 
3hrs, 5hrs, 7hrs, 9hrs and 24hrs) with and without BMPRII overexpression and their 
luciferase and β-galactosidase activities were determined. Reporter activation was observed 
after 7 hours of ligand stimulation and the highest activity was observed at the 24 hour time 
point (Supp Figures 4A-C). Together, these results indicate that the attenuation of caspase 
activities observed in these cells might be due to the activation of BMP signalling. 
Next, we tested whether the anti-caspase effect of BMP signalling is mediated through the 
ALK3, ALK1 and BMPRII receptors. Overexpression of either BMPRII or type I receptors 
ALK3 and ALK1 individually, have no discernible effect on basal caspase activation (Figure 
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5C). Interestingly, co-expression of ALK1 and BMPRII significantly inhibits both basal and 
ST-induced caspase activity HEK293T cells (Figure 5C-D and Supp Figure 5).  
Mutations in either ALK1 or BMPRII receptor impair the BMPRII-ALK1 pathway  
Since ALK1 has been shown to form a complex with BMPRII (23), we investigated whether 
both receptors work synergistically to regulate BMP signalling pathway. To do this, we used 
the BMP-responsive 3GC2-Lux reporter assay system to monitor BMP signalling (22). 
Overexpression of BMPRII alone and co-expression of BMPRII with ALK3 synergistically 
elevated the basal level of luciferase activity, which was consistent with our previous 
observations (5) (Figure 6A). Co-expression of BMPRII and ALK1 receptors generated 
reporter activity to a level comparable to that achieved by co-expression of BMPRII and 
ALK3 receptors, indicating that both BMPRII and ALK1 regulate BMP signalling in a 
synergistic manner (Figure 6A).  
Having demonstrated that the BMPRII and ALK1 receptors work synergistically to activate 
the BMP signalling pathway, we then investigated the effects of ligands including BMP4 and 
BMP9 on BMPRII receptor (Figure 6B). We found that HEK293T cells co-expressing 
BMPRII and stimulated with either BMP4 or BMP9 showed increased reporter activation 
compared with cells expressing BMPRII alone (Figure 6B). Furthermore, we found BMP9 
but not BMP4 ligand significantly increased ALK1-BMPRII-mediated reporter activation 
compared with cells transfected with BMPRII and stimulated with either BMP4 or BMP9 
ligand (Supp Figures 6A-B). We previously showed that mutations in the BMPR2 gene 
significantly reduced BMPRII-ALK3-mediated reporter activation. Among the mutations 
investigated, the p.D485G mutant was unable to interact with either ALK3 or ALK6 receptor 
and failed to activate the BMP-responsive reporter in the absence and presence of ALK3 
and ALK6 receptor overexpression and BMP4 ligand stimulation (5). In this study, we found 
that in the presence of this mutation, BMPRII-ALK1 mediated reporter activation was also 
significantly reduced both in the absence and presence of BMP9 stimulation (Figure 6C and 
Supp Figure 7A). Similarly, while testing the effect of ALK1 mutations (p.S333I and 
p.R111Q)  identified in hereditary haemorrhagic telangiectasia (HHT) patients (24-26), we 
found that BMPRII-ALK1 mediated reporter activation was significantly reduced (Figure 6D). 
Furthermore, BMP9-stimulated reporter activation was significantly reduced in cells 
overexpressing ALK1 mutations (p. D179A, p.S333I and p.R111) compared with the wild-
type receptor (Supp Figure 7B). Collectively, these data suggest that mutations in either the 
BMPRII or ALK1 receptor impinge upon the BMPRII-ALK1 pathway.  
Mutations found in the BMPR2 gene identified in PAH cases impair BMPRII-ALK1 
interactions 
We previously showed that the BMPRII receptor interacts with both ALK3 and ALK6 
receptors and pathogenic BMPR2 mutations impair these interactions (17). In this study, we 
first investigated whether BMPRII interacted with the ALK1 receptor and then determined the 
effect of BMPR2 mutations on BMPRII-ALK1 interactions. For this investigation, we 
employed our previously established cell-based protein-protein interactions assay, which 
was successfully used for determining the efficiency of interactions of BMPRII with ALK3 and 
ALK6 receptors (5,27). The assay system was based on the mammalian version of yeast two 
hybrid screen (27). Briefly, the activation domain (AD) was fused with the intracellular part of 
the BMPRII receptor, whilst the ALK1 lacking the extracellular domain was fused with DNA 
binding domain (DBD). The dual-reporter was co-transfected with both the ALK1-DBD and 
BMPRII-AD. In the event of no interaction, the cells generate only the upstream β-
galactosidase protein (Figure 7A). In the event of BMPRII-ALK1 interactions, both luciferase 
and β-galactosidase activities are generated.  
Co-expression of BMPRII and ALK1 constructs generated both luciferase and β-
galactosidase read outs indicating an interaction between these two proteins (Figure 7B). 
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However, we found that the efficiency of interactions of BMPRII with ALK1 was 26-fold 
weaker compared with the interactions between BMPRII and ALK3 receptors. We next 
investigated the effects of a wide range of BMPR2 mutations found in patients suffering from 
either PAH or congenital heart defects on BMPRII-ALK1 interactions. All mutations tested 
significantly impaired the efficiency of interactions between ALK1 and BMPRII proteins 
(Figure 7C). 
DISCUSSION 
The vascular remodelling observed in PAH lungs is caused by abnormal apoptosis of 
PASMCs and PAECs, but the underlying mechanisms by which apoptosis is controlled in 
PAH have remained elusive. Here, we report a novel mechanism which demonstrates that 
the dysregulated apoptosis in PAH is controlled via the BMPRII-Bcl-xL axis.  
This study shows in a number of ways that BMPR2 haploinsufficiency modulates the 
preferential expression of the anti-apoptotic Bcl-xL over the pro-apoptotic Bcl-xS transcripts 
both in PAH patients and in an animal model. First, we found preferential expression of the 
anti-apoptotic Bcl-xL transcripts in circulating leucocytes of PAH patients with and without 
BMPR2 mutations. Second, the increased expression of Bcl-xL transcripts was also 
observed in lungs of a PAH patient who had undergone combined heart and lung 
transplantation. The BMPR2 mutations included in this study are nonsense, insertion, and 
deletion mutations, and hence transcripts harbouring these alleles are likely to be degraded 
through the nonsense-mediated decay (NMD) pathway, creating a state of haploinsufficiency 
(5). Finally, in the chronic hypoxic rat lungs which showed a diminished level of BMPR2 
transcripts, the ratios of Bcl-xL to Bcl-xS and Bcl-xL to GAPDH were increased. Consistent 
with our observations, elevated levels of Bcl-xL protein were also found in pulmonary artery 
of chronic hypoxia treated rats with vascular remodelling (28).   
Many signalling pathways such as p38MAPK, ERK1/2, JAK/STAT, TNF, NF-κB and PI3K 
are activated and/or dysregulated in PAH patients. Previous observations suggest that each 
of these pathways is capable of contributing to the preferential expression of Bcl-xL 
transcripts. For example, ERK1/2 activates the p90RSK, which potentiates the transcription 
factor CREB and induces the expression of Bcl-xL and Bcl-2 transcripts (29,30). Additionally, 
ECs derived from idiopathic PAH (IPAH) patients show elevated levels of phosphorylated 
ERK1/2 and Bcl-xL expression leading to apoptosis resistance (31). TNF-α has been shown 
to activate both pro-apoptotic and anti-apoptotic pathways. Whilst it induces apoptosis by 
activating caspase-8 and -10, its anti-apoptotic activity is mediated via NF-κB, which induces 
the expression of anti-apoptotic Bcl-2 family of proteins (32-34). The PI3K/AKT pathway 
inhibits the expression of Bcl-xL transcripts by inhibiting the activation of FoxO transcription 
factor (35,36). These observations suggest that regulation of Bcl-xL transcripts may also 
occur through a process that is independent of BMPR2 mutation. 
Having established that the expression of Bcl-xL transcripts increased in vivo, we then 
proved that BMPRII controls the expression of Bcl-xL transcripts. Firstly, we showed that in 
PAH-PASMCs harbouring the pathogenic BMPR2 (p.R899X) mutation, the expression of 
anti-apoptotic Bcl-xL transcripts was greatly increased, indicating that BMPRII dysfunction 
might potentiate resistance to apoptosis. Secondly, siRNA knock-down of either the BMPR2 
or ALK1 genes inhibited the expression of Bcl-xL in PAECs. Finally, overexpression of either 
BMPRII receptor or BMP9 stimulation increased the expression of Bcl-xL in HEK293T cells. 
These observations suggest cell-specific effects of BMPRII dysfunction on the preferential 
expression of Bcl-xL transcripts. BMPRII deficiency promotes the expression of Bcl-xL 
transcripts in PASMCs, whilst inhibits it in ECs. Thus, the increased expression of Bcl-xL 
transcripts may contribute to differential apoptotic effects in these cells.  
Consistent with previous observations, we found that dysfunctional BMPRII signalling 
exerted anti-apoptotic phenotype in PASMCs whilst deficiency of this receptor led to 
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apoptosis in PAECs (4,17,23) . We observed that overexpression of BMPRII receptor 
promoted cell survival and this effect was greatly reduced in the presence of pathogenic 
BMPR2 mutations. We provided extensive evidence that the pro-survival effect of BMPRII 
signalling was mediated through the ALK1 receptor and that these two receptors worked 
synergistically. Firstly, caspase activity was greatly reduced following co-expression of 
BMPRII with ALK1 but not with ALK3 receptor; activation of the BMP9/ALK1/BMPRII axis in 
endothelial cells showed anti-apoptotic phenotypes (4,37). Secondly, cells co-expressed with 
BMPRII and ALK1, promoted BMP-responsive reporter activity and mutation either in 
BMPRII or in ALK1 impaired the reporter activation. Finally, we demonstrated that BMPRII 
interacted with the ALK1 receptor and in the event of pathogenic BMPR2 mutations, the 
efficiency of this interaction was greatly reduced. These observations support that 
stoichiometric imbalance in the BMPRII-ALK1 receptor complex may contribute to 
dysfunctional signalling leading to impaired apoptosis (5).      
The involvement of anti-apoptotic Bcl-xL protein in developing apoptosis resistance in many 
cancers is well documented, but the underlying mechanisms by which preferential 
expression of the Bcl-xL transcripts is regulated in PAH is not known. Based on our 
observations, we propose that either BMPR2 mutation or BMPRII receptor deficiency 
potentiates the expression of Bcl-xL transcripts leading to apoptosis resistance in PASMCs 
(Figure 7D). In PAECs, BMPRII deficiency reduces the Bcl-xL expression leading to anti-
survival effects. The pro-survival phenotype of PAECs is mediated via the BMPRII and ALK1 
receptors. The ALK1 receptor works synergistically with the BMPRII and in the event of 
pathogenic BMPR2 mutations, the BMPRII-ALK1-mediated signalling is greatly reduced 
which increases the susceptibility of endothelial cells to undergo apoptosis but not sufficient 
to trigger PAH. A critical reduction in BMPRII-mediated signalling or the presence of an 
additional stimulus may trigger apoptosis-resistance of PASMCs leading to vascular 
remodelling.   
Currently, neither any cure nor biomarker for PAH is known. Given the fact that antisense 
RNAs, small molecule agents such as fluoxetine and sodium nitroprusside and established 
drugs including ABT-263 (Navitoclax), which reduced the level of Bcl-xL protein reversed 
vascular remodelling in experimental models of PAH and adult T cell leukaemia indicate the 
potential of targeting this protein for therapeutic intervention (38,39). Although increased Bcl-
xL expression was observed in preclinical and PAH cases, the major limitation to developing 
Bcl-xL as a potential biomarker is that only a small number of patient samples were 
investigated in this study. Further epidemiological studies including various classes of PAH 
patients matched with healthy subjects together with analytical and clinical validations are 
required to determine whether Bcl-xL can be used as a novel biomarker in PAH.  
In summary, we have demonstrated that BMPRII deficiency impairs apoptosis by modulating 
the alternative splicing of Bcl-x transcripts, a finding observed in circulating leukocytes, lungs 
of PAH patients, hypoxic PAH rat lungs as well as in disease relevant human PASMCs and 
PAECs. Whilst BMPRII deficiency elicits anti-apoptotic effects in PASMCs, the receptor 
dysfunction induces pro-apoptotic responses in PAECs. The pro-survival effects of BMPRII 
are mediated through the ALK1 but not the ALK3 receptor in PAECs/HEK293T cells. BMPRII 
interacts with the ALK1 receptor and in the event of pathogenic BMPR2 mutations, this 
interaction is greatly reduced resulting in impaired signalling events. We propose that 
assessing Bcl-x transcripts in patient samples offers the opportunity for developing a novel 
biomarker and that targeting the BMPRII-Bcl-xL axis may provide a novel therapeutic 
intervention in PAH.  
MATERIALS AND METHODS 
Patient and control populations 
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Ethical approval for these studies was obtained from Papworth Hospital ethical review 
committee (Ethics Ref 08-H0304-56+5) and Trent Multi-Centre Research Ethics Committee 
(MREC/02/4/003) for the human tissues used and patients gave the written informed 
consents. Control samples are healthy individuals, all of which have no mutations in the 
BMPR2 gene. Human lung tissues are from a PAH subject harbouring a BMPR2 mutation 
(p.835X) who underwent combined heart and lung transplantation. The control human lung 
RNAs are from a commercially available source (Clontech Laboratories, Inc.). 
Isolation of PASMCs 
Isolation of PASMCs was described elsewhere (40,41). PAH-PASMCs were isolated from 
the proximal pulmonary arterial vessel segment (5-8mm diameter) obtained from the lung 
sample of a HPAH patient with a pathogenic BMPR2 mutation (p.R899X) undergoing lung 
transplantation. PASMCs of wild type (bmpr2 +/+) and knock-in mice harbouring the PAH-
associated bmpr2 nonsense mutation (p.R899X) were derived from explants.  
The luminal surface of the pulmonary artery was cut to open and endothelium was gently 
scrapped off using scalpel blade. The adjacent adventitia was stripped off and the medial 
explants were cut into 4-9 mm2 sections. These segments were then plated into T25 cm2 
flasks and allowed to adhere. DMEM containing 20% FBS and antibiotic 
(Penicillin/Streptomycin)- antimycotic (Amphotericin B) was added to the flasks after 2 hours 
(40,41). Cells were grown to confluency and used between passages 4-10. The phenotype 
of the isolated cells was confirmed by immunostaining using antibody to smooth muscle-
specific -actin (Sigma, UK). 
RNA isolation, cDNA synthesis and reverse Transcriptase PCR (RT-PCR) 
RNAs were isolated from mammalian cells and circulating leukocytes using either TRI-
Reagent (Sigma) or RNeasy Purification Kit (Qiagen, UK). cDNAs were synthesized using 
random primers and MMLV Reverse Transcriptase (Promega, UK) following manufacturer’s 
protocol. Total lung tissue RNA was extracted using the TRIzol method (Invitrogen, Thermo 
Fisher Scientific, UK). 2 µg RNA was then reverse transcribed using Thermoscript RT-PCR 
kits (Invitrogen, Thermo Fisher Scientific, UK). The PCR was carried out using Hi-Fidelity 
Extensor Master Mix (ABgene). Quantitative PCR for determining transcripts of bmpr2, and 
β-2 microglobulin (β-2mg) were performed using TaqMan Gene Expression Assay (Applied 
Biosystems, UK) on either 7900HT Fast Real-Time PCR system (Applied Biosystems, UK) 
or Step One Plus (Applied Biosystems, UK) according to the manufacturer’s protocol. 
Cell culture, transient transfection and enzymatic assay  
Cell culture and transfections were carried out as described elsewhere (5),(42),(43). 
GeneJammer transfection reagent (Stratagene, Agilent Technologies, USA) was used for 
transfection of the plasmids. The amount of plasmid DNAs transfected into the HEK293 and 
HEK293T cell lines varied from assay to assay (from 30 ng to 1 g). 24 hours after 
transfection, cells were treated with compounds in DMEM containing 0.1% FBS for an 
additional 24 hours. Cell lysate was prepared using 1X reporter lysis buffer (Promega, UK) 
as described earlier (17,18) and Luciferase and β-galactosidase activities were determined 
with the Dual-light Reporter Assay (Applied Biosystems, UK) using either an ORION-II or an 
ORION-L Plate Luminometer (Berthold Technologies, UK) according to the manufacturer’s 
protocols.  
Quantification of apoptosis and cell survival activity 
To determine the rate of apoptosis in HEK293, PASMCs and ECs, cells were seeded at 
0.2X105 per well in a white 96 well plate as described elsewhere (17,18). Twenty-four hours 
later, the medium was replaced by either fresh DMEM/0.1% FBS alone or containing BMP9 
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(1-10ng/ml) (R&D Systems), BMP4 (10ng/ml) (R&D Systems, UK), 2, 3 DCPE hydrochloride 
(5-20 µM) (TOCRIS, Bioscience, UK) and assays were carried out 24 hours after the 
treatment. For induction of apoptosis, cells were treated with staurosporine (TOCRIS, 
Bioscience, UK) for overnight at a concentration of 1.25µM. Apoptosis assays were carried 
out using Caspase-Glo® 3/7 Assay (Promega, UK) following manufacturer’s instruction. 
Luminescence was recorded using either an ORION-II or an ORION-L Plate Luminometer 
(Berthold Technologies, UK) at 30 and 60 minutes intervals. The cell survival activity was 
determined using CellTiter-Glo Cell Viability Assay (Promega, UK).  
Short interfering RNA (siRNA)-mediated knock-down of ALK1 and BMPR2 genes  
siGENOME SMART pool siRNAs (Dharmacon) were used to knock down ALK1 and BMPR2 
genes. The siGENOME SMARTpool is a mixture of 4 siRNAs, all designed to target different 
regions of the single gene of interest. PAECs were transfected with siRNAs either in 96 well 
plate (1X104) or 6-well plate (1X106) using Dharmafect 1 (Dharmacon, USA) following 
manufacturer’s protocol and incubated for 72 hours as previously described (43).  
Generation of constructs for protein-protein interactions assay 
The coding sequence of human ALK1 (accession number BC017715) lacking the first amino 
acid was cloned into BamHI and XbaI sites of pTN111 vector (27). The resulting plasmid 
contains a N-terminal DNA binding domain (DBD) adjacent to the human ALK1, the fidelity of 
which was verified by restriction analyses and sequencing. Efficiency of protein-protein 
interactions between ALK1 and BMPRII in mammalian cells was determined as previously 
reported (https://www.nature.com/protocolexchange/protocols/261). In brief the intracellular 
domain of BMPR2 was fused with VP-16 activation domain (5) whilst ALK1 was fused with a 
DBD. Plasmids encoding both fusion proteins were transfected into HEK293T cells together 
with the pTN114 dual reporter plasmid (5). In the event of an interaction both reporter 
proteins will be generated with the ratio of reporter activities producing a measure of the 
efficiency of protein-protein interactions.  
Details of the other expression constructs used in this study are available upon request.    
Statistics 
Statistical analysis was performed following paired Student’s t-test.  Comparison of multiple 
means was carried out using ANOVA followed by Tukey’s post hoc test.   
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FIGURE LEGENDS 
Figure 1 
Increased expression of Bcl-xL transcripts in circulating leukocytes and lungs of PAH 
patients. (A) Alternative splicing of the Bcl-x gene. Selection of the upstream 5’ splice site 
(5’ss) generates the anti-apoptotic Bcl-xL long isoform, while the downstream 5’ splice site 
produces the pro-apoptotic short isoform, Bcl-xS. (B) Reverse transcriptase polymerase 
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chain reaction (RT-PCR) analysis of Bcl-xS and Bcl-xL transcripts derived from circulating 
leukocytes of PAH patients with and without BMPR2 mutations. Controls 1-6 are RNAs 
derived from healthy subjects whilst Control 7 is commercially available RNA (Clontech). (C) 
Quantification of the RT-PCR image. (D) RT-PCR analysis of Bcl-x transcripts in human lung 
tissue from a PAH subject harbouring a BMPR2 mutation (p.835X) who underwent combined 
heart and lung transplantation. The control lung RNAs are from a commercially available 
source (Clontech).  (E) Quantification of RT-PCR by image analysis. The mean densities of 
bands derived from three independent experiments are shown. **P<0.01, ***P<0.001 
compared with control as indicated.  
Figure 2 
Determination of the alternative splicing of Bcl-x pre-mRNA in hypoxic PAH rat lungs. (A) 
Quantification of the BMPR2 transcript relative to β-2-microglobulin (b2mg) in hypoxic rat 
lungs by quantitative PCR. (B) As in Figure 1D, with lung samples derived from normoxic 
and hypoxic rats (n=6). (C) Quantification of the Bcl-xL vs Bcl-xS ratio of RT-PCR. (D) 
Quantification of the relative Bcl-xL vs GAPDH ratio of RT-PCR.  **P<0.01 compared with 
normoxia.  
Figure 3  
BMPR2 mutation impairs apoptosis through up-regulating the expression of Bcl-xL 
transcripts in PASMCs. (A) Determination of the alternative splicing of Bcl-x pre-mRNA in 
human PASMCs. RT-PCR analysis of Bcl-x transcripts in human PASMCs from a PAH 
subject harbouring the BMPR2 mutation (p.R899X). The hTERT-PAH-PASMCs are the 
p.R899X-PAH PASMCs which were immortalized with the expression of catalytic subunit of 
human telomerase (hTERT) gene (Nasim et al, unpublished data). (B) Quantification of RT-
PCR (n=4). (C) Diagram depicting the roles of Bcl-xL and Bcl-xS isoforms in apoptosis. (D) 
Differential effects of BMP9 ligand on apoptosis as determined by caspase 3/7 activities in 
PASMCs derived from wild-type and mutant mice harbouring the pathogenic BMPR2 
mutation (p.R899X) (n=6). Apoptosis was induced by the established chemical staurosporine 
(ST, 1.25µM). **P<0.01, ***P<0.001 compared with cells treated with ST only. (E) Diagram 
depicting the role 2,3 DCPE hydrochloride (TOCRIS), which selectively inhibits the activity of 
Bcl-xL isoforms on apoptosis. (F) Selected inhibition of Bcl-xL by 2,3 DCPE compound 
induces apoptosis in PAH-PASMCs in a dose-dependent manner (n=4). Concentrations of 
the BMP9 ligand and DCPE compound are indicated below graphs.  ***P<0.001 compared 
with untreated cells. Data are presented as mean ± SEM from 3–6 independent 
experiments.   
Figure 4  
Pro-survival effects of BMPRII is mediated through Bcl-xL and pathogenic BMPR2 mutations 
impair the pro-survival activity. (A) Either BMPRII or ALK1 down-regulates the expression of 
Bcl-xL transcripts in PAECs. RT-PCR analysis of Bcl-x transcripts in human PAECs 
transfected with 30nM of siRNAs targeting either the BMPR2 or ALK1 gene. Cells were 
harvested 48 hours after siRNA transfection. (B) Quantification of RT-PCR (n=4). (C) RT-
PCR analysis of Bcl-x transcripts in HEK293T cells either transfected with a construct 
containing the BMPR2 gene or stimulated with BMP9 (10ng/ml) ligand. (D) Quantification of 
RT-PCR (n=4). (E) Either BMPRII or ALK1 deficiency by means of siRNA knock-down 
promotes apoptosis in PAECs as determined by caspase 3/7 activities (n=9). Cells were 
treated with siRNAs for 48 hours. (F) Diagram of the BMPRII domain structure depicting the 
ligand binding (LB), transmembrane (TM), kinase (KD) and C-terminal extension (CTD). The 
numbers below indicating relative amino acids, whilst the mutations tested are indicated 
above. (G) Mutations in the BMPR2 gene identified in PAH cases impair cell survival as 
determined by the Cell-titre Glow Cell Viability Assay (Promega) (n=8). HEK293T cells were 
transfected either with the wild-type or mutant BMPRII receptors, ALK1 or ALK3 receptor 
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and the relative cell viability was determined. The value derived from untreated control cells 
was set as 100. ***P<0.001 compared with mock transfected cells, NS-non significant. Data 
are presented as mean ± SEM from 3–6 independent experiments.   
Figure 5  
BMP signalling inhibits apoptosis via the BMPRII-ALK1-mediated pathway. (A) Diagram 
depicting the effect of BMP signalling cascade on caspase 3/7 activities. (B) BMP signalling 
inhibits apoptosis in HEK293T cells (n=4) as determined by the Caspase-Glo 3/7 Assay 
(Promega). Cells treated with apoptosis-inducing agent staurosporine (1.25µM) and 
stimulated with BMP4 ligand (10ng/ml) for 16 hours. BMPRII receptor inhibits both basal (C) 
and (D) staurosporine-induced apoptosis through the ALK1 receptor (n=4). HEK293T cells 
transfected with either BMPRII, ALK1 and ALK3 receptors alone or BMPRII in combination 
with ALK1 and ALK3 receptors. Apoptosis was induced by treating the cells with 
staurosporine (1.25µM) for 16 hours (D).  ***P<0.001 compared with untreated (B), BMPR-II 
overexpressed (C) and ST-induced (D) cells. Data are presented as mean ± SEM from 3–6 
independent experiments.        
Figure 6  
Mutations in either BMPRII or ALK1 receptors impair the BMPRII-ALK1-mediated signalling. 
(A) The efficiency of BMPRII-ALK1 signalling is comparable to that of BMPRII-ALK3 as 
determined by the BMP-responsive 3GC2-Lux reporter assay (n=8). HEK293T cells 
transfected with the reporter plasmids together with BMPRII, ALK1, ALK3 and ALK6 
receptors. (B) Promotion of BMPRII-mediated signalling by BMP4 and BMP9 ligands. 
HEK293T cells transfected with the reporter plasmids together with BMPRII and stimulated 
with either BMP4 (10ng/ml) or BMP9 (10ng/ml) ligands for overnight (n=8). (C) Mutation in 
the kinase domain of BMPRII receptor (p.D485G) significantly reduced BMPRII-ALK1-
mediated reporter activation. HEK293T cells transfected in combination with either wild-type 
or mutant BMPRII receptor with and without ALK1 (n=8). (D) As (C), cells transfected in 
combination with wild-type and mutant ALK1 receptor with and without BMPRII (n=6). The 
luc-gal activity of the untreated control cells was set as 100. Data are presented as mean ± 
SEM from 3–6 independent experiments.  ***P<0.001 compared with either untreated or as 
indicated.    
Figure 7 
Interaction of ALK1 and BMPRII determined by mammalian two hybrid protein-protein 
interaction assay (27). (A) Outline of the BMPRII-ALK1 interactions assay, which is based on 
our previously established mammalian version of yeast two-hybrid screen (27). The assay 
was developed in such that in the event of no interaction, only β-gal protein will be produced. 
An interaction between BMPRII and ALK1 generates both β-gal and luciferase proteins. (B) 
The efficiency of the interaction of BMPR-II with either ALK3 or ALK1. HEK293T cells 
transfected with plasmids encoding BMPRII fused to the activation domain (BMPRII-AD) and 
ALK1 fused to the DNA binding domain (ALK1-DBD) compared to reporter alone (TN114). 
The efficiency of the interaction between BMPRII and ALK1 was set as 100 (n=8). (C) 
Mutations in the BMPR2 gene identified in both familial and sporadic PAH cases significantly 
reduce BMPRII-ALK1 interactions (n=10). As (B), cells were co-transfected in combination 
with either wild-type or mutant BMPR-II receptor together with ALK1-DBD and pTN114 
reporter. The relative luc-gal ratio in cells overexpressing mutant BMPRII and ALK1 
compared to the wild-type BMPRII receptor. Data are presented as mean ± SEM from 3–6 
independent experiments. SV40- SV40 promoter, D/A unit- deactivation/activation unit for 
downstream transcription (27). ***P<0.001 compared with reporter transfected with BMPR-II-
AD and ALK1-DBD plasmids. AD indicates activation domain; DBD, DNA-binding domain. 
(D) Model depicting the regulation of apoptosis resistance in PAH. In PASMCs, either 
BMPR2 mutations or BMPRII receptor deficiency potentiate the expression of Bcl-xL 
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transcripts leading to apoptosis resistance. In contrast, in PAECs, the receptor deficiency 
reduces the Bcl-xL expression leading to anti-survival effects. The pro-survival phenotype of 
PAECs is mediated via the BMPRII and ALK1 receptors. Both ALK1 and ALK3 receptors 
work synergistically with the BMPRII and in the event of pathogenic BMPR2 mutations, the 
efficiency of interactions of BMPRII with type I receptors is greatly reduced (5,17) which 
increases the susceptibility of PASMCs and PAECs to undergo impaired apoptotic pathway 
but not sufficient to trigger PAH. The presence of an additional stimulus may further 
exacerbate the apoptosis-resistance process leading to vascular remodelling. Thus, the Bcl-
x gene may represent a potential biomarker and druggable target for PAH. Straight arrows 
indicate activation; T-shapped line indicates inhibition. 
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SUPPLEMENTARY INFORMATION 
Figure legends 
Supplementary Figure 1 
Effect of BMPR2 mutation on apoptosis in mouse PASMCs as determined by caspase 3/7 
activities. PASMCs were derived from wild-type and mutant mice harbouring the pathogenic 
BMPR2 mutation (p.R899X). The activity level of caspases 3 and 7 was attenuated in mutant 
(p.R899X) cells compared with wild-type (n=8). ***P<0.001 compared with wild-type. 
Supplementary Figure 2 
Effects of siRNA knock-down on BMPR2 and ALK1 transcripts as determined by qPCR.  
Reduced levels of BMPR2 and ALK1 transcripts were observed in cells transfected with 
siRNAs at a concentration of 30nM compared with that of controls (siControl). Quantification 
of the relative BMPR2 vs GAPDH (A) and ALK1 vs GAPDH (B) ratios of qPCR (n=4).  
***P<0.001 compared with non-targeted siRNA.  
Supplementary Figure 3 
PAECs treated with BMP9 ligand elicited no discernible effect on the preferential expression 
of Bcl-x. (A) RT-PCR analysis of Bcl-xS and Bcl-xL transcripts in PAECs stimulated with 
BMP9 ligand (10ng/ml).  (B) Quantification of the RT-PCR images (n=4). The RT-PCR of 
GAPDH was used as an internal standard. NS-non significant. 
Supplementary Figure 4 
The BMP signalling promoting activity of BMP4 ligand and BMPRII receptor. (A) Diagram 
depicting the BMP signalling cascade as determined by the BMP responsive 3GC2-Lux 
reporter assay. HEK293T cells transfected with the 3GC2-Lux reporter were stimulated with 
the ligand (10ng/ml) at various time points (30 mins, 1h, 3hrs, 5hrs, 7hrs, 9rs and 24hrs) 
without (B) and with BMPRII (C) overexpression and their luciferase and β-galactosidase 
activities were determined (n=6). The luc-gal activities of cells at 0h time point were set as 
100. **P<0.01, ***P<0.001 compared with control treated for 0 hour. 
Supplementary Figure 5 
ALK1 and BMPRII significantly inhibit staurosporine (ST)-induced caspase activity. 
HEK293T cells overexpressed with ALK1, ALK3 and BMPR-II receptors were treated with 
apoptosis-inducing agent staurosporine (1.25µM) and stimulated with BMP4 ligand 
(10ng/ml) for 16 hours (n=4). The rate of apoptosis was determined using the Caspase-Glo 
3/7 Assay (Promega). ***P<0.001 compared with untreated control, NS-non significant. 
Supplementary Figure 6 
Effects of ALK1 on BMP4 and BMP9-mediated signalling as determined by the 3GC2-Lux 
reporter assay. HEK293T cells co-expressing 3GC2-Lux, BMPRII, ALK3 and ALK1 and 
stimulated with either BMP4 (A) or BMP9 (B) at a concentration of 10ng/ml (n=4).  ALK1-
BMPRII-mediated reporter activation was significantly increased compared with cells 
stimulated with either of BMP4 or BMP9 ligands. The luc-gal activity of ligand stimulated 
cells was set as 100. ***P<0.001 compared with ligand stimulated control, NS-non 
significant. 
 Supplementary Figure 7 
Effects of BMPR2 and ALK1 mutation on BMP9-mediated signalling as determined by the 
reporter assay. Mutation in either BMPRII or ALK1 receptor significantly reduced BMP9-
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mediated reporter activation.  (A) Mutation in the kinase domain of BMPRII receptor 
(p.D485G) significantly reduced BMP9-ALK1-mediated reporter activation. HEK293T cells 
transfected in combination with either wild-type or mutant BMPRII receptor with and without 
ALK1 (n=8). (B) As (A), cells transfected in combination with wild-type and mutant ALK1 
receptor with and without BMPRII (n=6).  The luc-gal activity of BMP9 ligand stimulated cells 
was set as 100. ***P<0.001 compared with ligand stimulated control.  
 
